The hearing will evaluate key developments in China's economy, military capabilities, and foreign relations, during 2020. Panelists will address the Chinese Communist Party's perceptions of its strategic environment and domestic legitimacy, as well as recent changes in its approach to foreign policy; assess China's current strengths and weaknesses in its foreign policy, military capabilities, and economy; review the economic and security implications for the United States of China's approach to Taiwan and the South China Sea, and; examine the implications for the United States of China's relationships with India and Iran.
The hearing will examine China’s views of and approach to strategic competition with the United States. Panelists will first assess U.S.-China strategic competition over the last 20 years in the economic, military, and ideological domains. The hearing will then assess how China views this competition playing out in the United Nations and key regions of the world. Finally, it will examine how the U.S.-China strategic competition might evolve in the future, including the prospects for a kinetic conflict.
This hearing will examine China’s growing influence in Africa and assess the implications of this influence for the United States. Panelists will analyze the strategic goals of China’s Africa policy and Africa’s significance to Beijing’s broader political and foreign policy interests. The hearing will then assess China’s economic activity in Africa, including its desire for commodities and resources, investment in critical infrastructure and sectors, and role in Africa’s growing digital economy. Finally, it will examine China’s growing security presence on the continent, including the evolution of Sino-African military-to-military relations, Chinese participation in UN peacekeeping operations, and China’s efforts to establish a permanent military presence on the continent to support its geopolitical and economic goals.
This hearing will examine China’s efforts to improve its national healthcare system and the implications for the United States. It will look at China’s recent efforts to meet the basic healthcare needs of its citizens, who in many cases remain severely underserved by China’s healthcare system. It will discuss how China seeks to use digital healthcare to both address basic systemic deficiencies and develop cutting-edge solutions to emerging healthcare problems. The hearing will also address the role that access to healthcare data—including U.S. healthcare data—plays in China’s development plans, and the extent to which U.S. firms and researchers enjoy reciprocal access to China’s healthcare data.
This virtual public roundtable discussion “A ‘China Model?’ Beijing’s Promotion of Alternative Global Norms and Standards” assesses the intentions behind China’s efforts to revise international governance institutions, norms, and values. It examines Beijing’s vision for a revised global order, attempts to identify whether a distinguishable “China model” exists, and assesses the extent to which Beijing is seeking to export such a model to other countries.
A public hearing on “A ‘China Model?’ Beijing’s Promotion of Alternative Global Norms and Standards” was unable to be held on the originally scheduled date, March 13, 2020, due to the Sergeant at Arms' decision to temporarily limit access to the Capitol Complex. Witness testimony has since been accepted and posted below. Questions for the record solicited by the Commission will be similarly be posted below once available.
This hearing will examine China’s ability to project military power and influence beyond its shores, with an emphasis on the country’s development of expeditionary capabilities. An official from the U.S. Department of Defense will provide testimony on how the Administration views China’s power projection and how such capabilities further China’s plans to reorder the Indo-Pacific and other key regions to its advantage. The first panel of experts will explore why and how China is developing expeditionary capabilities, with a focus on the Belt and Road Initiative (BRI) as a vehicle for testing and justifying these capabilities. The second panel will focus on the ‘‘nuts and bolts’’ of China’s expeditionary capabilities, including the PLA’s efforts to improve its logistics organization and expand its access to overseas bases. The third panel will examine how China’s activities in South and Southeast Asia, Africa, and Latin America and the Caribbean further its development of expeditionary capabilities.
The U.S.-China Economic and Security Review Commission’s first hearing in 2020 will examine the internal dynamics of China’s financial system; China’s increasingly rapid integration into global financial markets; and the risks this poses to U.S. investors and savers. The first Panel examines China’s overall capital requirements and systemic challenges to raising new capital. The second panel identifies and evaluates methods different actors in the Chinese economy use to raise capital and access financing. The third panel is designed to assess the exposure of U.S. investors to the growing integration of Chinese securities into global capital markets, with a particular emphasis on index inclusions and Chinese companies’ engagement with U.S. equities markets.
The hearing will review key developments in the U.S.-China relationship in 2019. Panel 1 will evaluate developments in China’s political economy and the impact of U.S.-China trade frictions on the Chinese economy. Panel 2 will assess the implications of Chinese military activities and modernization in 2019 for the United States and U.S. allies and partners. Panel 3 will review the implications of economic, political, and security developments between China and Taiwan for regional security, and explore the escalating situation in Hong Kong.
The hearing will assess China’s role in global health, pharmaceuticals, and medical products. In addition, it will examine the activities of Chinese health and biotech firms in the United States, and U.S. access to China’s health market. Finally, the hearing will consider the implications for U.S. public health and national security of growing U.S. dependence on Chinese health products.